Phillips-Medisize creates center of excellence for connected health and drug-delivery devices

When Phillips-Medisize (Hudson, WI) was acquired by Molex LLC (Lisle, IL) last year, Phillips-Medisize President and CEO Matt Jennings declared that the deal would help it to become “a global leader in connected health solutions.” That ambition reached a new milestone this week with the announcement of an initial investment in expansion of the capabilities of a Molex facility in Little Rock, AR, to include an FDA-registered manufacturing center of excellence for connected health and drug-delivery devices.

One of the world’s largest interconnect companies, Molex designs and manufactures electronic, electrical and fiber-optic systems. At the time of the purchase, Jennings stressed the inherent synergies of Molex’s global scale in electronics and Phillips-Medisize’s strength in designing and manufacturing innovative products for medical device customers.

The 380,000-square-foot facility in Little Rock will establish a new manufacturing site for Phillips-Medisize’s medical business with capabilities for filling, drug handling, electronics and connected devices. This investment aims to combine the innovative solutions and knowledge of Molex’s existing electronics production operations with Phillips-Medisize’s proven platform of drug-delivery and medical device expertise, said the company in a press release.

The construction of purpose-built cleanrooms, as well as FDA registration and ISO 13485 certification, are scheduled to be completed in the second quarter of 2018, when the first customer’s production will commence.

In addition to serving as a center of excellence for connected health and drug-delivery devices, “this facility will allow us to accommodate large programs requiring extensive assembly and molding operations, in cleanroom and other controlled environments, within a compressed timeframe,” said Jennings in a prepared statement. “The facility will have a particular focus on mid- to high-volume diagnostics, medical device and drug-delivery systems that integrate electronics and digital applications, and will provide us with the additional space needed to reach our growth objectives over the coming years,” added Jennings. 

This will be the company’s sixth expansion in the past six years to support long-term growth of its medical contract manufacturing business. In June 2017, the company completed a new 80,000 square feet facility in Menomonie, WI, and the previous year it opened a 17,000-square-foot dedicated clinical and pilot build facility for drug-delivery and combination devices at the same location. In November 2015, the company doubled the size of the New Richmond, WI, medical device facility, and in late 2014, expanded its Finland facility.

Comments (0)

Please log in or to post comments.
  • Oldest First
  • Newest First
Loading Comments...